In short
Vosilasarm, also known as EP0062 or RAD-140, is a new drug being studied in clinical trials for patients with advanced or metastatic breast cancer. This article explores the ongoing research on Vosilasarm, its potential benefits, and what patients should know about participating in these trials.
At a glance
- Drug Name
- Vosilasarm (EP0062, RAD-140)
- Drug Type
- Oral selective androgen receptor modulator (SARM)
- Target Condition
- Advanced or metastatic AR+/HER2-/ER+ breast cancer
- Trial Phase
- Phase 1/2
- Main Objectives
- Evaluate safety, tolerability, pharmacokinetics, and efficacy
- Key Eligibility Criteria
- Women 18+, specific breast cancer type, prior treatments
- Primary Endpoints
- Dose-limiting toxicities, adverse events, optimal dosage
- Secondary Endpoints
- Pharmacokinetics, objective response rate, survival measures
What is VOSILASARM?
VOSILASARM, also known as EP0062 or RAD-140, is a new medication being studied for the treatment of advanced breast cancer. It belongs to a class of drugs called selective androgen receptor modulators (SARMs), which are designed to target specific tissues in the body, particularly those affected by breast cancer.
How Does VOSILASARM Work?
VOSILASARM works by interacting with androgen receptors (AR) in the body. Androgen receptors are proteins that play a role in the development and progression of certain types of breast cancer. By targeting these receptors, VOSILASARM may help to slow down or stop the growth of cancer cells.
What Conditions Does VOSILASARM Treat?
VOSILASARM is being studied for the treatment of a specific type of breast cancer known as AR+/HER2-/ER+ breast cancer. This means the cancer is:
- AR+ (Androgen Receptor positive): The cancer cells have androgen receptors on their surface.
- HER2- (Human Epidermal Growth Factor Receptor 2 negative): The cancer cells do not have high levels of a protein called HER2.
- ER+ (Estrogen Receptor positive): The cancer cells have estrogen receptors on their surface.
Specifically, the clinical trial is focusing on patients with relapsed locally advanced or metastatic breast cancer. This means the cancer has either come back after previous treatment and spread to nearby areas (locally advanced), or it has spread to other parts of the body (metastatic).
Clinical Trial Information
VOSILASARM is currently being studied in a clinical trial. This trial is a Phase 1/2 study, which means it's designed to test the safety, effectiveness, and optimal dosage of the drug. The study is divided into two main parts:
- Module A: This part of the study aims to:
- Evaluate the safety and tolerability of VOSILASARM
- Determine the best dose of VOSILASARM when given alone
- Study how the drug is processed in the body (pharmacokinetics)
- Look at early signs of effectiveness
- Module B: This part of the study will:
- Test VOSILASARM in combination with other cancer treatments
- Continue to evaluate safety and effectiveness
Who Can Participate in the Trial?
The trial has specific criteria for who can participate. Some key points include:
- Women aged 18 or older
- Diagnosed with AR+/HER2-/ER+ breast cancer that has spread locally or to other parts of the body
- Cancer that has returned after previous treatments
- Postmenopausal status
- Previous treatment with certain types of cancer therapies
There are also several factors that might prevent someone from participating in the trial, such as certain medical conditions or previous treatments.
Potential Benefits and Risks
As with any experimental treatment, there are potential benefits and risks to participating in this clinical trial:
Potential Benefits:
- Access to a new treatment that may be effective against advanced breast cancer
- Close monitoring by healthcare professionals
- Contributing to medical research that could help future patients
Potential Risks:
- Unknown side effects or complications
- The treatment may not be effective for everyone
- Time commitment for study visits and procedures
Conclusion
VOSILASARM represents a promising new approach in the treatment of advanced AR+/HER2-/ER+ breast cancer. While it's still in the clinical trial phase, this medication could potentially offer new hope for patients who have not responded to other treatments. As always, patients should discuss their options with their healthcare provider to determine if participating in a clinical trial might be right for them.